RESUMO

Antibiotic prophylaxis in patients with cirrhosis and acute variceal bleeding is part of the standard of care according to most clinical guidelines. However, with recent evidence arguing against antibiotic prophylaxis, the role of this intervention has become less clear.

Assuntos

Antibacterianos , Antibioticoprofilaxia , Varizes Esofágicas e Gástricas , Hemorragia Gastrointestinal , Cirrose Hepática , Humanos , Antibioticoprofilaxia/métodos , Antibioticoprofilaxia/normas , Hemorragia Gastrointestinal/prevenção & controle , Hemorragia Gastrointestinal/etiologia , Varizes Esofágicas e Gástricas/etiologia , Varizes Esofágicas e Gástricas/diagnóstico , Cirrose Hepática/complicações , Antibacterianos/uso terapêutico , Antibacterianos/efeitos adversos , Guias de Prática Clínica como Assunto , Doença Aguda , Resultado do Tratamento

RESUMO

Cirrhosis is the end-stage of chronic liver disease and constitutes a leading cause of potential years of working life lost, especially in the Americas and Europe. Its natural history is characterized by an asymptomatic phase called compensated cirrhosis, followed by a rapidly progressive phase characterized by liver-related complications termed decompensated cirrhosis. Complications could be related to portal hypertension and/or liver dysfunction, including ascites, portal hypertensive gastrointestinal bleeding, encephalopathy, and jaundice. This review will discuss some of the most important precipitants of hepatic decompensation, including acute variceal bleeding, spontaneous bacterial peritonitis, and hepatic encephalopathy.

Assuntos

Varizes Esofágicas e Gástricas , Gastroenterologia , Encefalopatia Hepática , Humanos , Varizes Esofágicas e Gástricas/diagnóstico , Varizes Esofágicas e Gástricas/terapia , Hemorragia Gastrointestinal/diagnóstico , Hemorragia Gastrointestinal/etiologia , Hemorragia Gastrointestinal/terapia , Pacientes Internados , Cirrose Hepática/complicações , Cirrose Hepática/diagnóstico , Cirrose Hepática/terapia , Encefalopatia Hepática/diagnóstico , Encefalopatia Hepática/terapia , Ascite/etiologia , Ascite/terapia

RESUMO

It is unclear whether norfloxacin predisposes to infections by multidrug-resistant organisms (MDROs). We aimed to evaluate if patients with cirrhosis receiving norfloxacin prophylaxis at the time of the diagnosis of bacterial infections were more likely to present a multidrug-resistant isolate than those without prophylaxis. This is a cross-sectional study of hospitalized patients with cirrhosis and bacterial infections from Argentina and Uruguay (NCT03919032) from September 2018 to December 2020. The outcome variable was a multidrug-resistant bacterial infection. We used inverse probability of treatment weighting to estimate the odds ratio (OR) of norfloxacin on infection caused by MDROs considering potential confounders. Among the 472 patients from 28 centers, 53 (11%) were receiving norfloxacin at the time of the bacterial infection. Patients receiving norfloxacin had higher MELD-sodium, were more likely to have ascites or encephalopathy, to receive rifaximin, beta-blockers, and proton-pump inhibitors, to have a nosocomial or health-care-associated infection, prior bacterial infections, admissions to critical care units or invasive procedures, and to be admitted in a liver transplant center. In addition, we found that 13 (24.5%) patients with norfloxacin and 90 (21.5%) of those not receiving it presented infections caused by MDROs (adjusted OR 1.55; 95% CI: 0.60-4.03; p = 0.360). The use of norfloxacin prophylaxis at the time of the diagnosis of bacterial infections was not associated with multidrug resistance. These results help empiric antibiotic selection and reassure the current indication of norfloxacin prophylaxis in well-selected patients.Study registration number: NCT03919032.

Assuntos

Infecções Bacterianas , Peritonite , Humanos , Norfloxacino/uso terapêutico , Estudos Transversais , Infecções Bacterianas/tratamento farmacológico , Infecções Bacterianas/prevenção & controle , Infecções Bacterianas/microbiologia , Antibacterianos/uso terapêutico , Cirrose Hepática/complicações , Cirrose Hepática/microbiologia , Peritonite/microbiologia , Resistência a Múltiplos Medicamentos , Antibioticoprofilaxia/efeitos adversos

RESUMO

Mortality in cirrhosis is mostly associated with the development of clinical decompensation, characterized by ascites, hepatic encephalopathy, variceal bleeding, or jaundice. Therefore, it is important to prevent and manage such complications. Traditionally, the pathophysiology of decompensated cirrhosis was explained by the peripheral arterial vasodilation hypothesis, but it is currently understood that decompensation might also be driven by a systemic inflammatory state (the systemic inflammation hypothesis). Considering its oncotic and nononcotic properties, albumin has been thoroughly evaluated in the prevention and management of several of these decompensating events. There are formal evidence-based recommendations from international medical societies proposing that albumin be administered in individuals with cirrhosis undergoing large-volume paracentesis, patients with spontaneous bacterial peritonitis, those with acute kidney injury (even before the etiological diagnosis), and those with hepatorenal syndrome. Moreover, there are a few randomized controlled trials and meta-analyses suggesting a possible role for albumin infusion in patients with cirrhosis and ascites (long-term albumin administration), individuals with hepatic encephalopathy, and those with acute-on-chronic liver failure undergoing modest-volume paracentesis. Further studies are necessary to elucidate whether albumin administration also benefits patients with cirrhosis and other complications, such as individuals with extraperitoneal infections, those hospitalized with decompensated cirrhosis and hypoalbuminemia, and patients with hyponatremia.

Assuntos

Varizes Esofágicas e Gástricas , Encefalopatia Hepática , Síndrome Hepatorrenal , Peritonite , Albuminas/uso terapêutico , Ascite/tratamento farmacológico , Ascite/terapia , Varizes Esofágicas e Gástricas/complicações , Hemorragia Gastrointestinal/etiologia , Encefalopatia Hepática/tratamento farmacológico , Síndrome Hepatorrenal/etiologia , Humanos , Cirrose Hepática/tratamento farmacológico , Peritonite/microbiologia

RESUMO

Cirrhosis is characterised by a prolonged asymptomatic period in which the inflammation persists, increasing as the disease progresses. Characteristic of this is the increase in pro-inflammatory cytokines and pro-oxidant molecules which are determining factors in the development of multiple organ dysfunction. In the early development of cirrhosis, splanchnic arterial vasodilation, activation of vasoconstrictor systems (renin-angiotensin-aldosterone) and the sympathetic nervous system (noradrenaline) bring about bacterial translocation and systemic dissemination via portal circulation of bacterial products, and molecular patterns associated with damage, which exacerbate the systemic inflammation present in the patient with cirrhosis. Albumin is a molecule that undergoes structural and functional changes as liver damage progresses, affecting its antioxidant, immunomodulatory, oncotic and endothelial stabilising properties. Our knowledge of the properties of albumin reveals a molecule with multiple treatment options in patients with cirrhosis, from the compensated then decompensated phases to multiple organ dysfunction. Its recognised uses in spontaneous bacterial peritonitis, post-paracentesis circulatory dysfunction, acute kidney injury and hepatorenal syndrome are fully validated, and a treatment option has opened up in decompensated cirrhosis and in acute-on-chronic liver disease.

Assuntos

Síndrome Hepatorrenal , Peritonite , Albuminas/uso terapêutico , Síndrome Hepatorrenal/diagnóstico , Síndrome Hepatorrenal/etiologia , Humanos , Inflamação , Cirrose Hepática/complicações , Insuficiência de Múltiplos Órgãos/complicações , Peritonite/diagnóstico , Peritonite/tratamento farmacológico

RESUMO

INTRODUCTION AND OBJECTIVES: Spontaneous bacterial peritonitis (SBP) is a frequent complication to cirrhosis with an unclear long-term prognosis. We aimed to examine its effect on mortality in two independent patient cohorts. PATIENTS AND METHODS: We used Danish healthcare data on cirrhosis patients with a first-time paracentesis in 2000-2014 and data from three randomized controlled trials on satavaptan treatment of ascites conducted in 2006-2008. We used the Kaplan-Meier method to estimate cumulative mortality, and Cox regression to compare the confounder-adjusted mortality hazard for patients with vs. without SBP. RESULTS: In the Danish Healthcare Cohort, we included 1.282 patients of whom 133 (10.4%) had SBP. The SBP patients' cumulative 4-month mortality was 51.2% (95% CI: 43.0-59.9%) vs. 34.7% (95% CI: 32.0-37.6) in those without SBP. The SBP patients' confounder-adjusted mortality hazard was 1.54-fold higher (95% CI: 1.18-2.00) in the four months after paracentesis, but was not increased thereafter (confounder-adjusted mortality hazard 1.02, 95% 0.72-1.46). In the satavaptan trial data of 1,198 cirrhosis patients with ascites, the 93 patients with SBP had a cumulative 4-month mortality of 38.6% (95% CI: 29.3-49.7) compared with 11.4% (95% CI: 8.5-15.2) in those without. The SBP patients' confounder-adjusted mortality hazard ratio was 3.86 (95% CI: 2.44-6.12) during the first four months, and was 1.23 (95% CI: 0.54-2.83) thereafter. CONCLUSIONS: In both cohorts of patients with cirrhosis, an SBP episode had a high short-term mortality compared to patients without SBP, and had no lasting effect on the long-term mortality.

Assuntos

Infecções Bacterianas , Peritonite , Ascite/etiologia , Infecções Bacterianas/diagnóstico , Infecções Bacterianas/tratamento farmacológico , Humanos , Cirrose Hepática/complicações , Cirrose Hepática/diagnóstico , Peritonite/diagnóstico , Peritonite/tratamento farmacológico , Prognóstico , Ensaios Clínicos Controlados Aleatórios como Assunto , Fatores de Risco

RESUMO

OBJECTIVE: This study aimed to evaluate outcomes in cirrhotic patients diagnosed with spontaneous bacterial empyema (SBE) compared with those without this complication. METHODS: We performed a retrospective cohort study of cirrhotic patients from a tertiary care center. The primary outcome was time to death or liver transplantation (LT) within one year after diagnosis of infection. We integrated three groups: patients with SBE (group A), patients with spontaneous bacterial peritonitis (SBP; group B), and cirrhotic patients without SBP or SBE (group C), matched by age, model for end-stage liver disease-sodium (MELD-Na) score and year of infection. Outcomes were analyzed using a Cox regression model adjusted for cardiovascular risk factors and MELD-Na score. RESULTS: Between January 1999 and February 2019, 4829 cirrhotic patients were identified. Among them, 73 (1.5%) had hepatic hydrotorax, of whom 22 (30.1%) were diagnosed with SBE. Median age in group A was 58 years, 50% were men, and median MELD-Na was 21.5. Compared with group C, the hazard ratio of death or LT during the first year after infection was 2.98 (95% confidence interval [CI] 1.43-6.22, P = 0.004) for group A and 1.23 (95% CI 0.65-2.32, P = 0.522) for group B. CONCLUSIONS: Our results suggest that patients with SBE have a worse outcome during the first year after infection is diagnosed. Patients who develop SBE should be promptly referred for transplant evaluation. SBE may emerge as new indication that could benefit from MELD exception points.

Assuntos

Empiema , Doença Hepática Terminal , Estudos de Coortes , Humanos , Cirrose Hepática/complicações , Pessoa de Meia-Idade , Estudos Retrospectivos , Índice de Gravidade de Doença

RESUMO

ABSTRACT BACKGROUND: Spontaneous bacterial peritonitis (SBP) is a decompensation of cirrhosis with an in-hospital mortality ranging from 20% to 40%. OBJECTIVE: The purpose of this study is to analyze if EASL-CLIF definition of acute-on-chronic liver failure (ACLF) is able to predict mortality in cirrhotic patients with SBP. METHODS: Historical cohort study conducted in a public tertiary care teaching hospital. Data from medical records from January 2009 to July 2016 were obtained by searching the hospital electronic database for samples of ascites collected in the period. Electronic and physical medical records were analyzed and patients were included if they were over 18-years old, with cirrhosis and an ascites fluid compatible with SBP: 69 patients were included. Liver-specific scores were calculated and Kaplan-Meier survival analysis was used for univariate analysis and a stepwise approach to the Cox regression for multivariate analysis. RESULTS: All cause mortality was 44%, 56.5% and 74% for 28-, 90- and 365-day, respectively. The prevalence of ACLF was 58%. Of these, 65% grade 1, 17.5% grade 2 and 17.5% grade 3. In multivariate analysis, the use of proton-pump inhi­bitors, alanine transaminase lower than 40 U/L, hemoglobin higher than 9 g/dL, absence of ACLF and lower CLIF-SOFA and MELD scores were independently associated with higher survival for both 28- and 90-day interval. CONCLUSION: The presence of ACLF and higher CLIF-SOFA scores were independently associated with higher 28- and 90-day mortality in cirrhotic patients admitted due to SBP.

---

RESUMO CONTEXTO: A peritonite bacteriana espontânea (PBE) é uma descompensação da cirrose com uma mortalidade intra-hospitalar de 20% a 40%. OBJETIVO: O objetivo deste estudo é analisar se a definição de insuficiência hepática crônica agudizada (IHCA) como definido pelo consórcio EASL-CLIF é capaz de predizer mortalidade em pacientes cirróticos com PBE. MÉTODOS: Coorte histórica conduzida em um hospital de ensino público terciário. Foram obtidos dados de prontuários médicos de janeiro de 2009 até julho de 2016, buscando no banco de dados eletrônico do hospital por todas as amostras de ascite coletadas no período. Prontuários eletrônicos e físicos foram analisados e os pacientes com mais de 18 anos com cirrose e líquido de ascite compatível com PBE foram incluídos. Foram incluídos 69 pacientes. Escores específicos para o fígado foram calculados e a análise de sobrevida de Kaplan-Meier foi utilizada para a análise univariada, e uma abordagem progressiva para a regressão logística de Cox foi usada para a análise multivariada. RESULTADOS: A mortalidade por todas as causas foi 44%, 56,5% e 74% para 28-, 90- e 365-dias, respectivamente. A prevalência de IHCA foi de 58%. Desses, 65% grau 1, 17,5% grau 2 e 17,5% grau 3. Na análise multivariada, o uso de inibidores da bomba de prótons, alanina transaminase menor que 40 U/L, hemoglobina acima de 9 g/dL, ausência de IHCA e menores valores dos escores CLIF-SOFA e MELD foram independentemente associados com maior sobrevida para ambos intervalos de 28- e 90-dias. CONCLUSÃO: A presença de IHCA e maiores valores de CLIF-SOFA foram independentemente associados em maior mortalidade para pacientes cirróticos admitidos por PBE no intervalo de 28- e 90-dias.

Assuntos

Humanos , Peritonite , Insuficiência Hepática Crônica Agudizada/complicações , Prognóstico , Estudos Retrospectivos , Estudos de Coortes , Cirrose Hepática/complicações

RESUMO

Resumen: Los pacientes cirróticos hospitalizados presentan una alta prevalencia de infecciones bacterianas. Entre ellas, las denominadas infecciones espontáneas del cirrótico, que incluyen la peritonitis bacteriana espontánea, la bacteriemia espontánea y el empiema bacteriano espontáneo, constituyen un grupo particular, con un elevado riesgo de complicaciones y mortalidad. El presente trabajo tiene como objetivo describir y caracterizar las infecciones espontáneas en el cirrótico, la microbiología prevalente y su perfil de resistencia antibiótica, en 2 centros asistenciales de Montevideo-Uruguay. Se realizó un estudio transversal, descriptivo y multicéntrico, que incluyó pacientes con cirrosis hepática hospitalizados, en el periodo marzo 2018-marzo 2019. Del total de pacientes ingresados con cirrosis (156), 25 (16%) desarrollaron una infección espontánea del cirrótico. En 24 de estos pacientes (96%) la cirrosis se encontraba en estadios avanzados (Child-Pugh B-C, MELD＞15). La forma de presentación más frecuente fue la peritonitis bacteriana espontánea (52%), seguida de la bacteriemia espontánea (40%) y del empiema bacteriano espontáneo (8%). El aislamiento microbiológico fue posible en 17 casos (68%). En 12 de ellos (70%) se aislaron bacilos Gram negativos, en 4 (24%) bacilos Gram positivos, y Candida en 1 solo caso. Se identificaron 3 cepas productoras de BLEE (2 K. pneumoniae y 1 E. coli), y 4 microorganismos con otros perfiles de resistencia antibiótica (2 E. faecalis, 1 K. oxytoca, 1 E. cloacae). La prevalencia de microorganismos multirresistentes fue del 41%, siendo todos los casos en el grupo de adquisición nosocomial. La realización de otros estudios en esta área podría aproximarnos al conocimiento de la epidemiología local, para la optimización de los tratamientos empíricos dirigidos a los microorganismos más prevalentes, con el objetivo de mejorar el abordaje de las infecciones en los pacientes con cirrosis.

---

Abstract: Hospitalized cirrhotic patients present with a high prevalence of bacterial infections. Among them, spontaneous cirrhotic infections include spontaneous bacterial peritonitis, spontaneous bacteremia and spontaneous bacterial empyema, which constitute a particular group, with a high risk of complications and mortality. The work above aims to describe and characterize the spontaneous infections in the cirrhotic, the prevalent microbiology and its resistance profile, in 2 healthcare centers in Montevideo-Uruguay. A multicenter, descriptive, cross-sectional study was held, including hospitalized patients with liver cirrhosis, between March 2018 - March 2019. 25 (16%) of the 156 patients admitted with cirrhosis developed a spontaneous cirrhotic infection. 24 (96%) of these patients were in an advanced stage of their disease, (Child-Pugh B-C, MELD＞15). The most frequent presentation was the spontaneous bacterial peritonitis (52%), followed by the spontaneous bacteremia (40%) and the spontaneous bacterial empyema (8%). Microbiological isolation was possible in 17 cases (68%), of which 12 (70%) developed gram negative bacilli, 4 (24%) gram positive bacilli and 1 case Candida. 3 ESBL producing strains were identified, (2 K. pneumoniae and 1 E. coli), and other 4 microorganisms with different antibiotic resistance profile (2 E. faecalis, 1 K. oxytoca, 1 E. cloacae). The prevalence of multiresistant microorganisms was 41%, all of nosocomial acquisition. Research on this topic may provide more knowledge about the local epidemiology, improving the empiric treatments, targeting the most prevalent microorganisms, in order to better approach the infections in cirrhotic patients.

---

Resumo: Pacientes cirróticos hospitalizados presentam alta prevalência de infecções bacterianas. Dentre elas, as chamadas infecções cirróticas espontâneas, que incluem a peritonite bacteriana espontânea, a bacteremia espontânea e o empiema bacteriano espontâneo, constituem um grupo particular, com alto risco de complicações e mortalidade. O presente trabalho tem como objetivo descrever e caracterizar as infecções espontâneas em pacientes cirróticos, a microbiologia prevalente e seu perfil de resistência aos antibióticos, em 2 centros de saúde em Montevidéu-Uruguai. Foi realizado um estudo transversal, descritivo e multicêntrico, que incluiu pacientes hospitalizados com cirrose hepática, no período de março de 2018 a março de 2019. Do total de pacientes internados com cirrose (156), 25 (16%) desenvolveram infecção cirrótica espontânea. A cirrose estava em estágios avançados, em 24 desses pacientes (96%) (Child-Pugh B-C, MELD ＞ 15). A forma de apresentação mais frequente foi peritonite bacteriana espontânea (52%), seguida de bacteremia espontânea (40%) e empiema bacteriano espontâneo (8%). O isolamento microbiológico foi possível em 17 casos (68%). Em 12 deles (70%) foram isolados bacilos Gram negativos, em 4 (24%) bacilos Gram positivos e Candida em apenas 1 caso. Foram identificadas 3 cepas produtoras de ESBL (2 K. pneumoniae e 1 E. coli) e 4 microrganismos com outros perfis de resistência a antibióticos (2 E. faecalis, 1 K. oxytoca, 1 E. cloacae). A prevalência de microrganismos multirresistentes foi de 41%, todos no grupo de aquisição nosocomial. A realização de outros estudos nesta área poderá nos aproximar do conhecimento da epidemiologia local, para a otimização de tratamentos empíricos direcionados aos microrganismos mais prevalentes, com o objetivo de melhorar o manejo de infecções em pacientes com cirrose.

RESUMO

PURPOSE: Peritonitis is a serious complication of peritoneal dialysis and coagulase-negative Staphylococcus (CNS) is the most frequent cause of peritoneal dialysis (PD)-infections in many centers. This study aimed to investigate the molecular epidemiology of CNS isolated from PD-peritonitis in a Brazilian single center, focusing on the genetic determinants conferring methicillin resistance. METHODS: Bacterial strains were isolated from peritoneal fluid of patients presenting PD-peritonitis, identified by phenotypic and molecular methods, and those identified as CNS were submitted to mecA detection, SCCmec, pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST). RESULTS: Over the 18-year period of this study (1995-2011), a total of 878 peritonitis episodes were diagnosed in this unit, 115 were caused by coagulase-negative staphylococci of which 72 by Staphylococcus epidermidis. mecA gene was detected in 55 CNS (47.8%), more frequently on the more recent years. SCCmec type III was the most frequent cassette, followed by SCCmec type IV and SCCmec type II. A diverstity of pulsotypes was observed among the S. epidermidis isolates, but five clusters (based on the 80% cutoff) were identified. Diversified sequence types (ST02, ST05, ST06, ST09, ST23, ST59 and ST371) were detected. CONCLUSIONS: Detection of SCCmec type III among coagulase-negative Staphylococcus underscores the role of hospital environments as potential source of methicillin-resistant Staphylococcus causing peritonitis in PD patients.

Assuntos

Staphylococcus aureus Resistente à Meticilina/genética , Diálise Peritoneal/efeitos adversos , Peritonite/microbiologia , Infecções Estafilocócicas/diagnóstico , Infecções Estafilocócicas/epidemiologia , Staphylococcus epidermidis/genética , Coagulase , Humanos , Incidência , Staphylococcus aureus Resistente à Meticilina/enzimologia , Staphylococcus aureus Resistente à Meticilina/isolamento & purificação , Técnicas de Diagnóstico Molecular/métodos , Epidemiologia Molecular/métodos , Estudos Retrospectivos , Infecções Estafilocócicas/microbiologia , Staphylococcus epidermidis/isolamento & purificação

RESUMO

Infections are a frequent complication and a major cause of death among patients with cirrhosis. The important impact of infections in general and especially spontaneous bacterial peritonitis on the course of disease and prognosis of patients with cirrhosis has been recognized for many years. Nevertheless, such importance has recently increased due to the comprehension of infection as one of the most prominent risk factors for patients to develop acute-on-chronic liver failure. Furthermore, the issue of infections in cirrhosis is a focus of increasing attention because of the spreading of multidrug resistant bacteria, which is an emerging concern among physicians assisting patients with cirrhosis. In the present paper, we will review the current epidemiology of infections in patients with cirrhosis and particularly that of infections caused by resistant bacteria, demonstrating the relevance of the subject. Besides, we will discuss the current recommendations on diagnosis and treatment of different kinds of infections, including spontaneous bacterial peritonitis, and we will highlight the importance of knowing local microbiological profiles and choosing empirical antibiotic therapy wisely. Finally, we will debate the existing evidences regarding the role of volume expansion with albumin in patients with cirrhosis and extraperitoneal infections, and that of antibiotic prophylaxis of spontaneous bacterial peritonitis.

Assuntos

Infecções Bacterianas/microbiologia , Cirrose Hepática/complicações , Peritonite/microbiologia , Albuminas/uso terapêutico , Antibacterianos/uso terapêutico , Infecções Bacterianas/diagnóstico , Infecções Bacterianas/tratamento farmacológico , Infecções Bacterianas/mortalidade , Farmacorresistência Bacteriana Múltipla , Hidratação , Humanos , Cirrose Hepática/diagnóstico , Cirrose Hepática/mortalidade , Peritonite/diagnóstico , Peritonite/tratamento farmacológico , Peritonite/mortalidade , Substitutos do Plasma/uso terapêutico , Medição de Risco , Fatores de Risco , Resultado do Tratamento

RESUMO

INTRODUCTION AND OBJECTIVES: Limited data describe current SBP epidemiology and specific secondary SBP prophylactic regimens, leading to variable prescribing practices. This work aims to compare 90-day and one-year SBP recurrence and mortality based on secondary SBP antibiotic prophylaxis regimens. MATERIALS AND METHODS: We performed a retrospective cohort of patients >18 years with an SBP diagnosis from 2010 to 2015 at two academic institutions. Eligible patients had ascitic PMN counts ≥250cells/mm3 or a positive ascitic culture. Patients were compared based on secondary SBP prophylaxis regimens (i.e., daily, intermittent, or no prophylaxis). RESULTS: Of 791 patients with ascitic fluid samples, 86 patients were included. Antibiotic prophylaxis included daily (n=34), intermittent (n=36), or no prophylaxis (n=16). Nearly half of SBP episodes had a positive ascitic fluid culture; 50% were gram-negative pathogens, and 50% were gram-positive pathogens. Daily and intermittent regimens had similar rates of recurrence at 90-days (19.4% vs. 14.7%, p=0.60) and one-year (33.3% vs. 26.5%, p=0.53). Similarly, mortality did not differ among daily and intermittent regimens at 90-days (32.4% vs. 30.6%, p=0.87) or one-year (67.6% vs. 63.9%, p=0.74). When comparing any prophylaxis vs. no prophylaxis, there were no differences in 90-day or one-year recurrence or mortality. CONCLUSIONS: In patients with a history of SBP, our data indicate similar outcomes with daily, intermittent, or no secondary antibiotic prophylaxis. With available data, including ours, demonstrating a changing epidemiology for SBP pathogens, further data is required to determine if traditional approaches to secondary SBP prophylaxis remain appropriate.

Assuntos

Antibacterianos/administração & dosagem , Infecções Bacterianas/prevenção & controle , Peritonite/prevenção & controle , Idoso , Ascite/etiologia , Líquido Ascítico , Infecções Bacterianas/etiologia , Infecções Bacterianas/mortalidade , Estudos de Casos e Controles , Ceftizoxima/administração & dosagem , Ceftizoxima/análogos & derivados , Quimioprevenção/métodos , Ciprofloxacina/administração & dosagem , Estudos de Coortes , Feminino , Humanos , Estimativa de Kaplan-Meier , Cirrose Hepática/complicações , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Moxifloxacina/administração & dosagem , Análise Multivariada , Peritonite/etiologia , Peritonite/mortalidade , Modelos de Riscos Proporcionais , Recidiva , Estudos Retrospectivos , Combinação Trimetoprima e Sulfametoxazol/administração & dosagem , Cefpodoxima

RESUMO

INTRODUCTION AND AIM: Spontaneous bacterial peritonitis (SBP) is a life-threatening infection in patients with cirrhosis. However, it is unknown whether patients with SBP and cirrhosis who do not have active gastrointestinal bleeding have a poorer prognosis if treated with proton pump inhibitors (PPI). MATERIAL AND METHODS: We used the Taiwan National Health Insurance Database to identify 858 patients with SBP and cirrhosis who were administered PPIs and hospitalized between January 1, 2010, and December 31, 2013. One-to-two propensity score matching was performed to select a comparison group based on age, gender, and comorbidities. All patients obtained follow-up for 1 year. RESULTS: The overall 30-day, 90-day, and 1-year mortality was 27.9%, 49.0%, and 73.7%, respectively, in the PPI group and 25.6%, 43.8%, and 67.2%, respectively, in the non-PPI group. After adjusting the Cox regression model for age, gender, and comorbidities, the hazard ratios for PPIs regarding 30-day, 30- to 90-day, and 90-day to 1-year mortality were 1.074 (95% CI 0.917-1.257, P = 0.377), 1.390 (95% CI 1.154-1.673, P = 0.001), and 1.297 (95% CI 1.099- 1.531, P = 0.002), respectively. CONCLUSIONS: PPIs did not increase the short-term mortality of patients with SBP and cirrosis who did not have active gastrointestinal bleeding, but PPIs increased the long-term mortality risk. For these patients, physicians should discontinue PPIs as early as possible.

Assuntos

Infecções Bacterianas/mortalidade , Cirrose Hepática/tratamento farmacológico , Cirrose Hepática/mortalidade , Peritonite/mortalidade , Inibidores da Bomba de Prótons/efeitos adversos , Idoso , Infecções Bacterianas/diagnóstico , Infecções Bacterianas/microbiologia , Bases de Dados Factuais , Esquema de Medicação , Feminino , Humanos , Cirrose Hepática/diagnóstico , Cirrose Hepática/microbiologia , Masculino , Pessoa de Meia-Idade , Peritonite/diagnóstico , Peritonite/microbiologia , Inibidores da Bomba de Prótons/administração & dosagem , Estudos Retrospectivos , Medição de Risco , Fatores de Risco , Taiwan , Fatores de Tempo , Resultado do Tratamento

RESUMO

Bacterial infections are highly prevalent and a frequent cause of hospitalization and short-term mortality in patients with cirrhosis. Due to their negative impact on survival, antibiotic prophylaxis for bacterial infections in high-risk subgroups of patients with cirrhosis has been the standard of care for decades. Patients with prophylaxis indications include those at risk for a first episode of spontaneous bacterial peritonitis (SBP) due to a low ascitic fluid protein count and impaired liver and kidney function, patients with a prior episode of SBP and those with an episode of gastrointestinal bleeding. Only prophylaxis due to gastrointestinal bleeding has a known and short-time duration. All other indications imply long-lasting exposure to antibiotics - once the threshold requirement for initiating prophylaxis is met - without standardized criteria for re-assessing antibiotic interruption. Despite the fact that the benefit of antibiotic prophylaxis in reducing bacterial infections episodes and mortality has been thoroughly reported, the extended use of antibiotics in patients with cirrhosis has also had negative consequences, including the emergence of multi-drug resistant bacteria. Currently, it is not clear whether restricting the use of broad and fixed antibiotic regimens, tailoring the choice of antibiotics to local bacterial epidemiology or selecting non-antibiotic strategies will be the preferred antibiotic prophylaxis strategy for patients with cirrhosis in the future.

RESUMO

BACKGROUND AND AIMS: Spontaneous bacteremia is a poorly characterized infection in patients with cirrhosis. We compared the incidence of mortality and acute kidney injury in patients with spontaneous bacterial peritonitis and spontaneous bacteremia, and identified risk factors for mortality and acute kidney injury in patients with spontaneous bacteremia. METHODS: We performed a retrospective cohort study of patients with cirrhosis and spontaneous bacteremia or spontaneous bacterial peritonitis from 2008 to 2016 at Hospital Italiano, Buenos Aires. We compared the cumulative incidence of acute kidney injury and death between the two infections, and identified risk factors for these outcomes in patients with spontaneous bacteremia. RESULTS: Seventy-one patients with spontaneous bacteremia and 55 patients with spontaneous bacterial peritonitis were included. Most infections were nosocomial. Overall, 26% of bacteria were resistant and 11% multi-resistant. We found no significant association between acute kidney injury [subhazard ratio (sHR) 1.05 (95% confidence interval, CI 0.67-1.63, p = 0.83)] or death [sHR 1.15 (95% CI 0.60-2.20, p = 0.68)] and type of spontaneous infection in multivariate analyses adjusting for basal Model for End-Stage Liver Disease (MELD) score. In patients with spontaneous bacteremia, baseline MELD score was independently associated with acute kidney injury [sHR 1.07 (95% CI 1.03-1.11, p = 0.001)] and death [sHR 1.07 (95% CI 1.02-1.15, p = 0.03)]. CONCLUSIONS: Short-term acute kidney injury and mortality rates were similar in patients with spontaneous bacteremia and spontaneous bacterial peritonitis. Risk assessment of patients with spontaneous bacteremia can be performed with baseline MELD score.

Assuntos

Injúria Renal Aguda/mortalidade , Bacteriemia/mortalidade , Cirrose Hepática/mortalidade , Peritonite/mortalidade , Idoso , Argentina/epidemiologia , Feminino , Infecções por Bactérias Gram-Negativas/mortalidade , Infecções por Bactérias Gram-Positivas/mortalidade , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Fatores de Risco

RESUMO

Ascites is a major complication of cirrhosis. There are several evidence-based articles and guidelines for the management of adults, but few data have been published in relation to children. In the case of a pediatric patient with cirrhotic ascites (PPCA), the following questions are raised: How are the clinical assessment and ancillary tests performed? When is ascites considered refractory? How is it treated? Should fresh plasma and platelets be infused before abdominal paracentesis to prevent bleeding? What are the hospitalization criteria? What are the indicated treatments? What complications can patients develop? When and how should hyponatremia be treated? What are the diagnostic criteria for spontaneous bacterial peritonitis? How is it treated? What is hepatorenal syndrome? How is it treated? When should albumin be infused? When should fluid intake be restricted? The recommendations made here are based on pathophysiology and suggest the preferred approach to diagnostic and therapeutic aspects, and preventive care.

---

La ascitis es una complicación grave de la cirrosis. Existen numerosos artículos y guías basadas en la evidencia para adultos, pero poco se ha publicado para niños. Ante un paciente pediátrico con ascitis secundaria a cirrosis (PPAC), se plantean las siguientes preguntas: ¿Cómo se realiza la evaluación clínica y los exámenes complementarios? ¿Cuándo se considera que la ascitis es refractaria; cómo se trata? ¿Debe infundirse plasma fresco y plaquetas antes de la paracentesis abdominal para evitar el sangrado? ¿Cuáles son los criterios de hospitalización? ¿Cuáles son los tratamientos indicados? ¿Qué complicaciones puede presentar? ¿Cuándo y cómo debe tratarse la hiponatremia? ¿Qué criterios diagnósticos tiene la peritonitis bacteriana espontánea; cómo se trata? ¿Qué es el síndrome hepatorrenal; cómo se trata? ¿Cuándo debe infundirse albúmina? ¿Cuándo debe restringirse el aporte líquido? Las recomendaciones que efectuamos, basadas en la fisiopatología, sugieren el enfoque preferido para encarar sus aspectos diagnósticos, terapéuticos y los cuidados preventivos.

Assuntos

Cirrose Hepática/complicações , Cirrose Hepática/terapia , Desequilíbrio Hidroeletrolítico/etiologia , Desequilíbrio Hidroeletrolítico/terapia , Ascite/etiologia , Ascite/terapia , Criança , Humanos , Guias de Prática Clínica como Assunto

RESUMO

Ascites is a major complication of cirrhosis. There are several evidence-based articles and guidelines for the management of adults, but few data have been published in relation to children. In the case of pediatric patients with cirrhotic ascites (PPCA), the following questions are raised: How are the clinical assessment and ancillary tests performed? When is ascites considered refractory? How is it treated? Should fresh plasma and platelets be infused before abdominal paracentesis to prevent bleeding? What are the hospitalization criteria? What are the indicated treatments? What complications can patients develop? When and how should hyponatremia be treated? What are the diagnostic criteria for spontaneous bacterial peritonitis? How is it treated? What is hepatorenal syndrome? How is it treated? When should albumin be infused? When should fluid intake be restricted? The recommendations made here are based on pathophysiology and suggest the preferred approach to its diagnostic and therapeutic aspects, and preventive care.

---

La ascitis es una complicación grave de la cirrosis. Existen numerosos artículos y guías basadas en la evidencia para adultos, pero poco se ha publicado para niños. Ante un paciente pediátrico con ascitis secundaria a cirrosis (PPAC), se plantean las siguientes preguntas: ¿Cómo se realiza la evaluación clínica y los exámenes complementarios? ¿Cuándo se considera que la ascitis es refractaria; cómo se trata? ¿Debe infundirse plasma fresco y plaquetas antes de la paracentesis abdominal para evitar el sangrado? ¿Cuáles son los criterios de hospitalización? ¿Cuáles son los tratamientos indicados? ¿Qué complicaciones puede presentar? ¿Cuándo y cómo debe tratarse la hiponatremia? ¿Qué criterios diagnósticos tiene la peritonitis bacteriana espontánea; cómo se trata? ¿Qué es el síndrome hepatorrenal; cómo se trata? ¿Cuándo debe infundirse albúmina? ¿Cuándo debe restringirse el aporte líquido? Las recomendaciones que efectuamos, basadas en la fisiopatología, sugieren el enfoque preferido para encarar sus aspectos diagnósticos, terapéuticos y los cuidados preventivos.

Assuntos

Cirrose Hepática/diagnóstico , Cirrose Hepática/terapia , Ascite/diagnóstico , Ascite/terapia , Criança , Hospitalização , Humanos , Cirrose Hepática/fisiopatologia , Guias de Prática Clínica como Assunto

RESUMO

BACKGROUND: The clinical impact of relative adrenal insufficiency (AI) on patients with stable decompensated cirrhosis (DeCi) has not been yet elucidated. AIM: Explore the association between AI and outcome [death or liver transplantation (LT)] in patients with DeCi. MATERIAL AND METHODS: Patients with DeCi presenting no active complication have been included. Clinical and laboratory data, including serum levels of corticosteroid-binding globulin (CBG), interleukin (IL)-1b, IL-6 and tumor necrosis factor (TNFα) were recorded in each participant. Salivary cortisol (SC) and serum total cortisol (STC) were assessed at (T0) and 1 h (T60) after intravenous injection of 250 µg corticotropin. RESULTS: 113 consecutive patients were totally tested. Median SC was 3.9 ng/mL and 15.5 ng/mL and median STC was 10.7 µg/dL and 22.7 µg/dL at T0 and T60 respectively. The patients with AI [group 1, n = 34 (30%)] had significantly lower systolic blood pressure (106 ± 12 vs. 113 ± 13 mmHg, p = 0.05), serum sodium (133 ± 7 vs. 137 ± 12 mEq/ L, p = 0.04), HDL (29.9 ± 14 vs. 38.6 ± 18 mg/dL, p = 0.034) and albumin (2.7 ± 0.5 vs. 3.1 ± 0.5 g/dL, p = 0.002), but higher direct bilirubin (median: 1.6 vs. 0.8 mg/dL, p = 0.029) compared to those without AI [group 2, n = 79 (70%)]. Moreover, group 1 patients presented more frequently past history of spontaneous bacterial peritonitis (SBP) [10/34 (29.4%) vs. 6/79 (7.5%), p = 0.002]. AI was significantly associated with death [HR = 2.65, 95% C.I.: 1.55 - 4.52, p = 0.003 over a follow up period of 12 (6-48) months.] Conclusions. The presence of AI in patients with stable DeCi predispose to obvious clinical implications since it is associated with circulatory dysfunction, previous history of SBP and worse survival.

Assuntos

Insuficiência Adrenal/epidemiologia , Cirrose Hepática/cirurgia , Transplante de Fígado , Insuficiência Adrenal/diagnóstico , Insuficiência Adrenal/mortalidade , Adulto , Idoso , Biomarcadores/sangue , Distribuição de Qui-Quadrado , Feminino , Grécia/epidemiologia , Humanos , Hidrocortisona/sangue , Interleucina-1beta/sangue , Interleucina-6/sangue , Estimativa de Kaplan-Meier , Cirrose Hepática/diagnóstico , Cirrose Hepática/mortalidade , Transplante de Fígado/efeitos adversos , Transplante de Fígado/mortalidade , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Razão de Chances , Prevalência , Modelos de Riscos Proporcionais , Fatores de Risco , Saliva/metabolismo , Fatores de Tempo , Transcortina/análise , Resultado do Tratamento , Fator de Necrose Tumoral alfa/sangue

RESUMO

Objetivo: Establecer las características de peritonitis bacteriana espontánea en pacientes cirróticos con ascitis. Método: Se recopiló información de historias clínicas de pacientes cirróticos con ascitis ingresados en el servicio de gastroenterología. Resultados: el motivo de consulta más frecuente fue por aumento de la circunferencia abdominal (69,2%); somnolencia (29,9%), hematemesis (23,1%). El Child-Pugh fue 78,8% tipo B y 22,2% tipo C. Se evidenció asociación estadísticas entre la coinfección y peritonitis bacteriana espontánea (p = 0,013). Conclusión: La PBE es una complicación frecuente y grave de los pacientes con cirrosis hepática avanzada y ascitis. El diagnóstico y tratamiento precoz han conseguido mejorar el pronóstico en los últimos años.

---

Objective: To Establish the characteristics of spontaneous bacterial peritonitis in cirrhotic patients with ascites. Method: information from medical records of cirrhotic patients with ascites admitted to the gastroenterology was collected. Results: The most frequent reason for consultation was due to increased abdominal circumference (69.2 %); somnolence (29.9 %), hematemesis (23.1 %). The Child - Pugh was 78.8 % and 22.2 % type B type C statistical association between co-infection and spontaneous bacterial peritonitis (p = 0.013) was demonstrated. Conclusion: The PBE is a frequent and serious complication of patients with advanced liver cirrhosis and ascites. Early diagnosis and treatment have improved prognosis in recent years.